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CASE REPORT
INTRODUCTION
Cholangiocarcinoma is a rare malignancy,
consisting of 2% of all cases of malignancy.
Nevertheless, this is the second most frequent primary
malignancy of the hepatobiliary system after hepato-
cellular carcinoma.1 Cholangiocarcinoma which
involves bifurcatio areas is referred to as Klatskin
tumor,1,2 and it is the cholangiocarcinoma most
commonly found, for about 40-60%.3
Klatskin tumor has a poor prognosis with
a five-year survival rate as much as 10% and most
patients die within the first year.4 Surgery is the only
curative measure. However, tumors that have the
potential to be treated by surgery consisted of a small
percentage, between 5-20%.4
Endoscopic retrograde cholangio pancreato-
graphy (ERCP), other than being an important
diagnostic modality, also plays a role as a therapeutic
one. The success rate for stents placement for biliary
drainage is varied between 70-90%, although in
proximate tumors, especially those involving bifurcatio
areas, the number is lower.4
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ABSTRACT
Klatskin tumor is a cholangiocarcinoma in bifurcatio areas and related to poor prognosis. Surgery is
the only curative method, but endoscopy also has a role in diagnostic as well as therapeutic measures.
This report shall discuss a case of Klatskin tumor in which to establish diagnosis, multimodal imaging
using ultrasonography, computed tomography, endoscopic retrograde cholangiopancreatography (ERCP),
and tumor markers were used. For palliative therapeutic measures in this case, placement of plastic
stents by ERCP was performed. The procedure ERCP with stents placement can be an option in the
management of Klatskin tumor, in which surgery is not possible to be conducted.
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A case of patient with Klatskin tumor is reported
as well as the measures taken to establish the
diagnosis and its management. The discussion shall
focus on the role of ERCP, both as a diagnostic tool
and a therapeutic one.
CASE ILLUSTRATION
A male, 54 years old, presented with the chief
complaint of yellowish eyes since three months
before admission. At first, yellowish color could only
be found in the eyes, but then it started to spread to
other parts of the body. The patient was complaining
of pale-colored stool, urine with tea-like color, loss of
appetite and gradual weight loss + 30 kg in the last
three months, as well as itching sensation all over his
body. The patient smokes a pack of cigarettes a day
for 30 years and drinks traditional herbal medicine.
Since six months before admission, the patient
often felt an intermittent upper abdominal pain similar
to muscle aching and was nonradiating, his stomach
felt easily full, though it has nothing to do with food
intake and change of position as well as activity. The
patient had seeked for hospital care in other private
hospital and a computed tomography (CT) was
performed. The result of the diagnosis claimed that
there was a obstruction of biliary tract and surgery
was suggested, but it was not performed due to
financial reason. A month before admission, the
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patient felt that the upper abdominal pain he had  
experienced was worsening, accompanied by  
swelling of the abdomen and legs.  
Physical examination showed that the patient looked  
moderately ill, fully alert, stabile hemodynamics,  
afebrile temperature of 36.6°C, pale conjunctiva, and  
greenish yellow sclera. Through abdominal  
examination, hepatomegaly was palpated 5 cm below 
arcus costae, 15 cm below xyphoid process, blunt sides, 
smooth surface, jelly-like. Pain on palpation was found  
in the right hypocondriacal region, no shifting dullness  
was detected. His skin looked jaundice with slight  
squama. Laboratory results at admission showed  
anemia, elevated direct-bilirubin, and elevated trans- 
aminase  enzyme.  Chest  X-ray  showed  no  
abnormalities. On abdominal CT without contrast from  
the previous hospital showed dilation of intrahepatic  
biliary tract, enlargement of liver especially in the right  
lobe, normal pancreas, sludge and stone in the  
gallbladder, and did not appear enlarged lymph nodes  
paraaorta. 
From these data, the problem was identified as  
extrahepatic obstructive jaundice caused by  
cholangiocarcinoma. Abdominal ultrasonography  
(USG) examination showed enlargement of the right  
lobe of liver with flat surface and blunt side.  
The ecostructures of the right and left lobes were  
nonhomogenic, an anecoic space occupying lesion  
(SOL) was found in the left lobe and sludge was found  
in the gallbladder. The pancreas was normal, both left  
and right intrahepatic biliary tracts were enlarged,  
while periaortal lymph nodes were not enlarged.  
 From the first ERCP in which the stents had not  
been placed, images of the hilar region showed  
narrowing of the hepatic duct and filling defect  
contrast. However, after the procedure, the patient  
experienced post-acute cholangitis and then given  
antibiotics cefoperazone, ciprofloxacin, and metronida- 
zole. During the second ERCP, placement of  
stents was successfully performed, bilirubin level was  
gradually decreasing, and the patient experienced  
clinical improvement. From consultation with  
digestive surgical, an operation was planned, but the  
patient refused. The patient was then discharged with  
plastic stents placed and was advised regularly  
control. 
 
 
 
 
 
 
 
 
 
 
Figure 1. USG result showed dilation of intrahepatic biliary duct in 
the right and left lobes of the liver 
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Figure 2. ERCP result showed of hepatic duct stricture in hilar 
region and filling defect contrast 
DISCUSSION 
The patient had greenish jaundice, dark urine, pale 
stool and pruritus, aside from bilirubinuria, elevated 
gamma GT level and alkaline phosphatase as well as 
higher level of direct bilirubin in comparison to that of 
indirect bilirubin, thus a possibility of extrahepatic 
obstructive jaundice was considered,5 with  
a possibility of a malignancy as the cause. 
Biliary tract malignancy is a primary malignancy of  
the hepatobiliary system which is the second most  
frequently found after hepatocellular carcinoma.1  
Clinical features frequently found in cholangio- 
carcinoma are symptoms of obstruction of the biliary  
tract such as jaundice, pale fesces, tea-colored urine,  
and pruritus.2,4 These are consistent with the findings  
in this patient. About 90-98% of patients present with  
jaundice, and may be accompanied with other non- 
specific complaints such as weight loss 29%,  
abdominal pain 20%) and sometimes fever 9%.  
Itching sensation is also a fairly common complaint  
30%.3 Cholangiocarcinoma is usually identified in an  
advanced condition with systemic manifestation of  
malignancy, such as malaise, exhaustion, and weight  
loss.2 
Cholangiocarcinoma is more prevalent in males,  
and both the existence of stone in biliary tract and  
smoking are correlated to increased risk of  
cholangiocarcinoma.1,2 The factor of aging is also  
correlated with increased risk for cholangiocarcinoma,  
where 2/3 cases of cholangiocarcinoma occurred in  
individuals > 65 years old and an over ten times  
increase of risk occurred in those > 80 years old.2 Other  
than that, epidemiological factor should also be taken  
into consideration. In South East Asia, cases of  
cholangiocarcinoma are correlated to parasitic  
infections and chronic typhoid carrier, where cases of  
chronic typhoid carrier is correlated to a six-times  
increase of risk for hepatobiliary malignancy.2  
However, in these cases, adequate diagnostic work up  
for both risk factors had not been conducted. Risk  
factors for cholangiocarcinoma in this patient are male,  
smoking, stone in the biliary tract, and age.  
 USG is the main modality for cases with suspicion  
of obstruction bilier.2 Initial radiological examination 
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performed in this patient was USG, and it showed
dilation of bilateral intrahepatic biliary ducts without
dilation of extrahepatic biliary duct. The diagnosis of
hilar cholangiocarcinoma should be considered in cases
where dilated of intrahepatic ducts was found without
any dilatation in extrahepatic duct.2,6 The weakness of
USG examination is that it makes it possible to miss
perihiler, extrahepatic, and periampular tumors, and less
good for determining the extent of the tumor spread.2
CT can provide a better image for lesions of
intrahepatic masses, dilatation of intrahepatic ducts,
and local lymphadenopathy, although CT usually can
not provide clear image of the spread of the tumor.2 In
this case, a CT without contrast had been performed
six months before, and it showed a dilation of
intrahepatic biliary duct and sludge in the gallbladder,
no mass or lymph nodes enlargement was found.
During hospital stay, other CT was taken, this time
using contrast, and it showed dilatation of intrahepatic
biliary ducts and cyst in the left lobe of the liver which
did not enhance in contrast. There was also no lymph
nodes enlargement found.
Cholangiography (MRCP, ERCP) and percuta-
neous transhepatic cholangiography (PTC) are
important in early diagnosis of cholangiocarcinoma and
in evaluating resectability.2 In this case, selected ERCP
performed with a consideration other than as
a diagnostic modality can also be as a therapeutic
modality and the narrowing of the ductus hepaticus in
hilar region as well as a filling defect contras (see
figure 1).
These findings are consistent with Klatskin tumor.
Other than making it possible to take bile for cytology,
ERCP also allows stent placement in the purpose of
palliative care for non-resectable tumors.2
Eventhough positive results in cytology and
histology are hard to obtain by ERCP, both
are recommended to confirm the diagnosis of
cholangiocarcinoma. ERCP allows cytologic samples
to be obtained, which resulted positive in
approximately 30% cases of cholangiocarcinoma.2
A combination of brush cytology and biopsy increased
positive results up to 40-70%, although negative
result in cytology does not eliminate the possibility
of malignancy.2 Inadequate samples are the main
 reason for failure. Brush cytology by endoscopy is
usually performed after sphincterotomy.7 Sensitivity
of brush cytology is largely varied, between 8 and
57%. Type and length of the brush as well as the
amount of time it takes to obtain a sample influence
cytology result, meanwhile obtaining cytologic
samples for three consecutive times increases
positive results up to 68%.7 Other literature mention
that brush cytology is relatively easy to perform and is
widely used, with a specificity of 100% while the low
sensitivity of 30-60%.4 Forceps biopsy and fine needle
biopsy require sphincterotomy, which in turn increases
the risk of complications. Fine needle biopsy has a
higher sensitivity of 85-90%,4 even though other
literature reported a lower result of 62%.7 Collection
of fluid from biliary tract can also be performed, but
its sensitivity is so low that it is rarely used.4 In this
case, a sample should have been obtained at the
moment the ERCP was performed, but sample
collection could not be conducted due to the stricture
being relatively too tight on the brush catheter.
There is no specific tumor marker for cholangio-
carcinoma. CA 19-9,8  carcinoembryonic antigen
(CEA), and CA-125 are the tumor markers most
frequently used for cholangiocarcinoma.2,8
The CA 19-9 level of this patient was 219.9 U/mL.
CA 19-9 increases in 85% of patients with
cholangiocarcinoma, it was also reported that
a CA19-9 level of over 100 U/mL has a sensitivity and
specificity of 75% and 80%, respectively.2 Other
study mentioned that CA 19-9 has a sensitivity and
specificity of 60% and 70% for biliary tract
malignancy.9 However, CA-19-9 level may increase
in obstructive jaundice with no malignancy, but
a steadily increasing level even after biliary
decom-pression indicates a malignancy.2
Concentration of CA 19-9 will be influenced with
the secretion status of patient’s and Lewis genotype,
thus these should be taken into consideration in
interpreting the result of tumor marker.10 CA 19-9 level
can increase in biliary tract and pancreas
malignancies, other than non-malignant conditions such
as gallstone, pancreatitis, cirrhosis, and cholecystitis.7,11
Other literature mentions that CA 19-9 level
before treatment is a prognostic factor where  levels
of greater than 300 U/mL has a three-times greater
risk for early death.12 Other than that, decreasing level
after therapy was correlated with increased survival
rate.12
In a study involving 55 patients with Klatskin
tumor diagnosed by cholangiography and CT scan,
49 among them had had stents placements, of which
28 (57%) patients succeded in the first effort while
8 (16%) patients succeded in the second, thus
the cumulative number of stents placement success
rate was 73%. However, only 20 (41%) patients
experienced satisfying biliary drainage.13 In resectable
cases, placement of biliary endoprosthesis can be
conducted instead of surgery, by which biliary
drainage can be restored and survival rate can be
increased,2 as well as increasing the quality of life.14
Endoscopic stent placement is correlated to high
success rate, acceptable morbidity, and low
mortality. ERCP is a primary modality for palliative
therapy of biliary obstruction caused by cholangio-
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carcinoma.15 To achieve adequate biliary drainage, a
previous try on stent placement in this patient had been
performed, but it had failed and it was just successful
in the second ERCP.
Complications often found in ERCP are
pancreatitis, hemorraghe, infection, and perforation.16
Incidence rate of pancreatitis post-ERCP is
1.9-11.7%.16 In sphincterotomy, the complications most
commonly found are bleeding, pancreatitis, and
perforation. The incidence of pancreatitis post-ERCP
and sphincterotomy is between 1.3-2.4%.17
Sphincterotomy by itself is a risk factor for bacterial
contamination in biliary tract because it facilitates
migration of the bacteria in transpapillary digestive
tract.8 The risk of cholangitis after ERCP currently is
very low, as much as 0.7%.8 If diagnostic ERCP was
performed without any measure to achieve biliary
drainage in the existence of obstruction, the incidence
of cholangitis would incrase ten times.8 This is caused
by the gastrointestinal-tract bacterial contaminated  the
sterile bile.8 Biliary obstruction due to hilar stricture
and intrahepatic biliary tract obstruction or stones are
technically difficult to perform decompression on, thus
the risk of cholangitis requires special attention.8 In the
first ERCP and sphincterotomy on this patient, acute
cholangitis occurred caused by the use of contrast
without adequate biliary drainage. To patient given
a combination of three antibiotics therapy for
gram-positive, gram-negative, and anaerobic bacteria,
which were ciprofloxacin, cefoperazone, and
metronidazole. Second ERCP was then performed with
stent placement.
The purpose of acute cholangitis therapy is to
control infection and to prevent sepsis. A therapy of
broad-spectrum antibiotic was given especially for
gram-negative enteric aerobic bacteria (Escherichia
coli, Klebsiella species, Enterobacter species),
gram-positive, and anaerobic Enterococcus
(Bacteroides fragilis, Clostridium perfringens).
The therapy is usually administered for short term of
10-14 days.18 An example of a first-line agent is
intravenous ciprofloxacin, which is administered
200-400 mg for every 12 hours. In patients with biliary
obstruction, only ciprofloxacin is excreted to the bile
in adequate amount, which is 20% of the peak serum
level, which is more than enough in comparison to that
of the minimum inhibitory concentration (MIC) for
gram-negative bacteria.18 There are several other first-
line drugs, such as intravenous metronidazole which is
suitable for anaerobic bacteria, ampicillin sulbactam
which is appropriate for enterococcus, and
cephalosporin. The second-line drug is imipenem
cilastatin, which has a highly-broad spectrum
(gram positive and negative as well as anaerobe).18
The use of piperacillin as prophylaxis in ERCP is not
correlated with the decreased incidence of post-ERCP
acute cholangitis.19 A meta analysis on the use of
prophylaxis antibiotics in ERCP does not show decrease
in the risk of cholangitis.8 However, failure of adequate
biliary drainage is an important risk factor for
cholangitis. Hence, prophylactic antibiotic is best be
administered in cases where adequate drainage would
possibly be failed to achieve, such as in patients with
malignancy in the hilar region.4 Prophylactic antibiotic
is given once before the procedure be performed4 and
if the procedure involves the use of contrast while
adequate drainage is not sufficient, antibiotic therapy
should be continued after drainage was achieved.4,8
Antibiotic should be bactericidal and has a good
penetrating potential in the hepatobiliary system.4
Effective ERCP for palliative therapy of the biliary
obstruction caused by malignancy, where metal stents
have patency duration longer compared to the plastic
ones.20 Financial analysis demonstrates that metal stints
shall be useful for patients who could survive for over
6 months, while plastic stents for those who are
predicted to survive for less than 6 months.2 In this
patient, plastic stent placement was selected due to
limitations in financial capability.
The median of patency duration of plastic stents
10-Fr is between 3-6 months. The incidence of stent
occlusion is varied between 20-50%.4 The cause of
the occlusion begins with the attachment of protein
and bacteria in the stent’s inner lining. In vitro
experiments, administration of antibiotic decreases the
attachment of bacteria on the stent. Thus, antibiotic
administration seems to be a logical option.4 Other than
that, there is a study which mention that administering
ursodeoxycolic acid may decrease the risk of
occlusion.4 Hence, this patient was given the antibiotic
ciprofloxacin and ursodeoxycolic acid before leaving
the hospital. However, a recent study on the use of
antibiotic and combination of antibiotic with
ursodeoxycolic acid demonstrates no correlation with
patency difference in group which was given none.4
This case seems to be successful in performing
palliative stent placement by ERCP. ERCP procedure
without adequate drainage may develop complications
such as the occurrence of post-ERCP cholangitis in
the patient. However, ERCP procedure with stent
placement can be an option in the therapy of Klatskin
tumor in which surgery is not possible to be performed.
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